Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and OmniAb (OABI)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Merck & Company (MRK) and OmniAb (OABI) with bullish sentiments.
End of Quarter Sale - 50% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Merck & Company (MRK)
BMO Capital analyst Evan Seigerman maintained a Buy rating on Merck & Company yesterday and set a price target of $135.00. The company’s shares closed last Friday at $119.63.
According to TipRanks.com, Seigerman is a 5-star analyst with an average return of
Currently, the analyst consensus on Merck & Company is a Moderate Buy with an average price target of $131.36, implying a 10.1% upside from current levels. In a report issued on March 19, Scotiabank also maintained a Buy rating on the stock with a $136.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
OmniAb (OABI)
In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on OmniAb. The company’s shares closed last Friday at $1.51.
According to TipRanks.com, Devarakonda is a 5-star analyst with an average return of
OmniAb has an analyst consensus of Strong Buy, with a price target consensus of $7.67.
Read More on MRK:
Disclaimer & DisclosureReport an Issue
- Winrevair’s Mixed Phase 2 Signal Leaves Merck’s Risk‑Reward Balanced, Supporting a Hold Rating
- Merck announces data from Phase 2 Cadence trial of Winrevair
- Wix downgraded, TripAdvisor upgraded: Wall Street’s top analyst calls
- Terns Pharmaceuticals downgraded to Market Perform from Outperform at BMO Capital
- Agilent receives FDA approval for PD-L1 1HC 22C3 pharmDx
